Epic Sciences has added a pair of private equity investors and another strategic investor with its series E round of $52 million. That puts it in an optimal spot for a potential IPO and for strategic dealmaking. The round was led by health care private equity firm Blue Ox Healthcare Partners, with participation by another health care PE group, Deerfield Management, and cancer radiotherapy company Varian Medical Systems Inc.
Epic Sciences has added a pair of private equity investors and another strategic investor with its series E round of $52 million. That puts it in an optimal spot for a potential initial public offering and strategic deal-making. The round was led by health care private equity firm Blue Ox Healthcare Partners, with participation by another health care PE group Deerfield Management and cancer radiotherapy company Varian Medical Systems Inc.
Novocure has been working for a long time to establish the market for its device-based cancer treatment based on Tumor Treating Fields (TTF). Its Optune system was first approved by FDA in 2011 to treat glioblastoma (GBM) after chemotherapy, in the fall of 2015 it was kicked up to a first-line GBM treatment for adults in combination with chemotherapy temozolomide.
